Journal
NATURE MEDICINE
Volume 18, Issue 3, Pages 456-U159Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2665
Keywords
-
Funding
- National Center for Research Resources of the US National Institutes of Health [P40RR017447]
- US National Institutes of Health [NIAMS-5R21AR057515, NIAM-R01AR043052, 1K12HD05195801]
- US National Institute of Child Health and Human Development (NICHD)
- Office of Research on Women's Health (ORWH)
- Office of Dietary Supplements (ODS)
- US National Institute of Aging (NIA)
Ask authors/readers for more resources
Aging reduces the number of mesenchymal stem cells (MSCs) that can differentiate into osteoblasts in the bone marrow, which leads to impairment of osteogenesis. However, if MSCs could be directed toward osteogenic differentiation, they could be a viable therapeutic option for bone regeneration. We have developed a method to direct MSCs to the bone surface by attaching a synthetic high-affinity and specific peptidomimetic ligand (LLP2A) against integrin alpha 4 beta 1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affinity for bone. LLP2A-Ale induced MSC migration and osteogenic differentiation in vitro. A single intravenous injection of LLP2A-Ale increased trabecular bone formation and bone mass in both xenotransplantation studies and in immunocompetent mice. Additionally, LLP2A-Ale prevented trabecular bone loss after peak bone acquisition was achieved or as a result of estrogen deficiency. These results provide proof of principle that LLP2A-Ale can direct MSCs to the bone to form new bone and increase bone strength.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available